In postmenopausal women, morning salmon calcitonin decreased urinary CrossLaps/Cr approximately 3-6 hours after administration, followed by rebound.
In plain wordsIn postmenopausal women, morning calcitonin reduced a bone resorption marker temporarily, followed by rebound.
- Peptide
- Calcitonin-salmon
- Outcome
- DecreaseUrinary CrossLaps/Cr after morning administration
- Study
n = 9
- Comparator
- control 24 h study without intervention
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 200 IE · intranasal · 4-5 days before and during the second study, or 5 days before and during the third studyAs given in this study (human).
Source sentences
Both morning and evening administration of sCT significantly decreased the urinary excretion of CrossLaps/Cr approximately 3-6 h after administration with a subsequent rebound effect.
5 context sentences(design, population, supporting numbers)
The purpose of this study was to examine the effect of intranasal salmon calcitonin (sCT) administration (200 IE), given either in the morning (8:00) or evening (21:00), on the known circadian variation in biochemical markers of bone turnover.
An open, placebo-controlled, randomized, crossover study, with three 24 h studies of blood samples drawn every third hour and urine collected in 3 h aliquots was undertaken.
Subjects consisted of nine healthy postmenopausal women, aged 58 +/- 7 years.
Prior to this control study the participants were randomized to either morning (8:00) or evening (21:00) sCT (200 IE). sCT administrations were given 4-5 days prior to and during the second study.
After a washing-out period of 2 weeks the participants were given 200 IE of sCT at the reverse time of the day 5 days prior to and during the third study.